[Federal Register: August 29, 2005 (Volume 70, Number 166)]
[Proposed Rules]
[Page 50996]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr29au05-16]
========================================================================
Proposed Rules
Federal Register
________________________________________________________________________
This section of the FEDERAL REGISTER contains notices to the public of
the proposed issuance of rules and regulations. The purpose of these
notices is to give interested persons an opportunity to participate in
the rule making prior to the adoption of the final rules.
========================================================================
[[Page 50996]]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-269N]
Schedules of Controlled Substances: Placement of Embutramide Into
Schedule III; Extension of Comment Period
AGENCY: Drug Enforcement Administration (DEA), Department of Justice.
ACTION: Notice of proposed rulemaking; extension of comment period.
-----------------------------------------------------------------------
SUMMARY: The Drug Enforcement Administration (DEA) is extending the
comment period and time to request a hearing on the Federal Register
Notice of proposed rulemaking entitled ``Schedules of Controlled
Substances: Placement of Embutramide into Schedule III'' published on
July 29, 2005 (70 FR 43809).
DATES: The period for public comment that was to close on August 29,
2005, will be extended to September 28, 2005.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-269P'' on all written and electronic correspondence.
Written comments being sent via regular mail should be sent to the
Deputy Administrator, Drug Enforcement Administration, Washington, DC
20537, Attention: DEA Federal Register Representative/ODL. Written
comments sent via express mail should be sent to the Deputy
Administrator, Drug Enforcement Administration, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria,
VA 22301. Comments may be directly sent to DEA electronically by
sending an electronic message to dea.diversion.policy@usdoj.gov.
Comments may also be sent electronically through http://www.regulations.gov
using the electronic comment form provided on that
site. An electronic copy of this document is also available at the
http://www.regulations.gov Web site. DEA will accept electronic
comments containing MS Word, WordPerfect, Adobe PDF, or Excel file
formats only. DEA will not accept any file format other than those
specifically listed here.
FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section, Drug Enforcement Administration,
Washington, DC 20537, Telephone: (202) 307-7183.
SUPPLEMENTARY INFORMATION: DEA published a Notice of Proposed
Rulemaking (70 FR 43809) proposing the placement of embutramide into
Schedule III of the Controlled Substances Act (CSA). The proposed
scheduling action is based on a scientific and medical evaluation and
recommendation by the Department of Health and Human Services and an
evaluation of this and other information by DEA. On August 22, 2005,
DEA received a request for an extension of the period in which to
comment and request a hearing. The requestor indicated that the
additional time is necessary to review the scientific articles and
other information cited by DEA in support of its scheduling proposal.
Upon consideration of this request, a thirty day extension of the time
to comment and request a hearing is granted. This allows sufficient
time for interested persons to evaluate and consider all relevant
information and respond accordingly. Therefore, the comment period and
time to request a hearing is extended to September 28, 2005. Comments
must be received by the DEA on or before this date.
Dated: August 24, 2005.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 05-17163 Filed 8-26-05; 8:45 am]
BILLING CODE 4410-09-P